NASDAQ:PRQR ProQR Therapeutics (PRQR) Stock Price, News & Analysis → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Buy PRQR with Qtrade Free PRQR Stock Alerts $1.99 +0.13 (+6.99%) (As of 04/19/2024 ET) Add Compare Share Share Today's Range$1.87▼$2.0750-Day Range$1.86▼$2.5652-Week Range$1.11▼$3.29Volume134,020 shsAverage Volume152,108 shsMarket Capitalization$161.91 millionP/E RatioN/ADividend YieldN/APrice Target$3.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ProQR Therapeutics alerts: Email Address ProQR Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80.9% Upside$3.60 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.37) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.67 out of 5 starsMedical Sector639th out of 911 stocksPharmaceutical Preparations Industry279th out of 418 stocks 3.5 Analyst's Opinion Consensus RatingProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProQR Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.50% of the float of ProQR Therapeutics has been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProQR Therapeutics has recently decreased by 4.04%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRQR. Previous Next 2.6 News and Social Media Coverage News SentimentProQR Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ProQR Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of ProQR Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.65% of the stock of ProQR Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.37) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProQR Therapeutics is -5.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProQR Therapeutics is -5.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About ProQR Therapeutics Stock (NASDAQ:PRQR)ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Read More PRQR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRQR Stock News HeadlinesApril 20, 2024 | americanbankingnews.comCitigroup Increases ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00April 19, 2024 | globenewswire.comProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioApril 20, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 16, 2024 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above Fifty Day Moving Average of $2.16April 8, 2024 | finance.yahoo.comProQR Therapeutics N.V. (PRQR)March 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic DisordersMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing PlatformMarch 14, 2024 | finance.yahoo.comProQR Therapeutics Full Year 2023 Earnings: Misses ExpectationsApril 20, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 13, 2024 | globenewswire.comProQR Announces Year End 2023 Operating and Financial ResultsFebruary 18, 2024 | finance.yahoo.comPRQR Mar 2024 2.500 callFebruary 16, 2024 | wsj.comProQR Therapeutics N.V.February 15, 2024 | finance.yahoo.comProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA EditingJanuary 30, 2024 | stocknews.com4 Biotech Stocks With Massive Buy PotentialJanuary 19, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024January 19, 2024 | finance.yahoo.comProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024January 15, 2024 | finance.yahoo.comWhile institutions invested in ProQR Therapeutics N.V. (NASDAQ:PRQR) benefited from last week's 12% gain, individual investors stood to gain the mostJanuary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strategic Partnership and Promising Axiomer RNA Editing PlatformJanuary 5, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing CollaborationJanuary 5, 2024 | benzinga.comProQR Therapeutics Stock (NASDAQ:PRQR) Dividends: History, Yield and DatesJanuary 5, 2024 | finance.yahoo.comProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing CollaborationDecember 28, 2023 | finance.yahoo.comIs ProQR (PRQR) Stock a Solid Choice Right Now?December 9, 2023 | markets.businessinsider.comProQR’s Strategic Divestiture and Strong Financial Outlook Justify Buy RatingDecember 8, 2023 | finance.yahoo.comProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic AssetsNovember 21, 2023 | morningstar.comProQR Therapeutics NV PRQRNovember 9, 2023 | markets.businessinsider.comPositive Report for ProQR (PRQR) from Chardan CapitalNovember 9, 2023 | markets.businessinsider.comBuy Rating for ProQR Therapeutics: Robust RNA-Editing Patent Portfolio, Promising Preclinical Candidates, and Strong Financial PositionSee More Headlines Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/20/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRQR CUSIPN/A CIK1612940 Webwww.proqr.com Phone(188) 166-7000FaxN/AEmployees156Year FoundedN/APrice Target and Rating Average Stock Price Target$3.60 High Stock Price Target$5.00 Low Stock Price Target$2.00 Potential Upside/Downside+80.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,430,000.00 Net Margins-431.65% Pretax Margin-426.98% Return on Equity-56.71% Return on Assets-19.15% Debt Debt-to-Equity Ratio0.10 Current Ratio3.54 Quick Ratio3.54 Sales & Book Value Annual Sales$7.05 million Price / Sales22.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book3.62Miscellaneous Outstanding Shares81,360,000Free Float74,521,000Market Cap$161.91 million OptionableOptionable Beta0.21 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Domenico Valerio Ph.D. (Age 68)Founder & Independent Chairman of Supervisory Board Comp: $78.79kMr. Daniel Anton de Boer (Age 41)Founder, CEO & Member of Management Board Comp: $1.27MMr. Rene K. Beukema (Age 60)Chief Corporate Development Officer, General Counsel & Member of Management Board Comp: $974.24kDr. Gerard Platenburg (Age 60)Co-Founder & Chief Scientific Officer Comp: $23.42kMr. Jurriaan Dekkers (Age 48)Chief Financial Officer Ms. Sheila Sponselee (Age 40)Chief People & Operations Officer Ms. Sarah Cue KielyVice President of Investor Relations & Corporate CommunicationsMs. Sandra van der KolkJunior Financial ControllerMore ExecutivesKey CompetitorsTheseus PharmaceuticalsNASDAQ:THRXNGM BiopharmaceuticalsNASDAQ:NGMImmutepNASDAQ:IMMPKinnate BiopharmaNASDAQ:KNTEMerrimack PharmaceuticalsNASDAQ:MACKView All CompetitorsInstitutional OwnershipRFG Advisory LLCBought 32,000 shares on 4/11/2024Ownership: 0.039%Virtu Financial LLCBought 34,904 shares on 2/26/2024Ownership: 0.043%Citadel Advisors LLCBought 1,600 shares on 2/15/2024Ownership: 0.000%BNP Paribas Financial MarketsBought 9,200 shares on 2/7/2024Ownership: 0.020%Simplex Trading LLCSold 6,500 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions PRQR Stock Analysis - Frequently Asked Questions Should I buy or sell ProQR Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRQR shares. View PRQR analyst ratings or view top-rated stocks. What is ProQR Therapeutics' stock price target for 2024? 4 brokerages have issued 1-year target prices for ProQR Therapeutics' shares. Their PRQR share price targets range from $2.00 to $5.00. On average, they expect the company's stock price to reach $3.60 in the next twelve months. This suggests a possible upside of 80.9% from the stock's current price. View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts. How have PRQR shares performed in 2024? ProQR Therapeutics' stock was trading at $1.98 at the beginning of the year. Since then, PRQR stock has increased by 0.5% and is now trading at $1.99. View the best growth stocks for 2024 here. When is ProQR Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our PRQR earnings forecast. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics (NASDAQ:PRQR) issued its quarterly earnings results on Wednesday, March, 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The biopharmaceutical company had revenue of $3.54 million for the quarter, compared to analyst estimates of $27.88 million. ProQR Therapeutics had a negative net margin of 431.65% and a negative trailing twelve-month return on equity of 56.71%. What ETF holds ProQR Therapeutics' stock? Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). Who are ProQR Therapeutics' major shareholders? ProQR Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RFG Advisory LLC (0.04%). How do I buy shares of ProQR Therapeutics? Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRQR) was last updated on 4/20/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.